Brain rhythm attractor breakdown in Alzheimer's disease: Functional and pathologic implications.

Elissaios Karageorgiou1, Keith A Vossel2

  • 1Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA; Neurological Institute of Athens, Athens, Greece.

Summary

Alzheimer's disease (AD) is linked to sleep disorders via brain rhythm breakdown. Early tau pathology causes sleep disturbances, promoting amyloid-beta buildup and cognitive decline.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Functional Brain Systems: Reticular Formation01:13

Functional Brain Systems: Reticular Formation

The reticular formation is a complex network of gray and white matter located within the brainstem extending from the medulla to the midbrain.
Within the reticular formation, there are several distinct nuclei that can be classified into three broad categories. The Raphe nuclei are located along the midline of the brainstem. They are primarily known for their role in synthesizing and releasing serotonin, a neurotransmitter involved in regulating mood, appetite, sleep, and circadian rhythms. The...
5.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K